Introduction {#s1}
============

Duchenne muscular dystrophy (DMD) is an X-linked recessive disease which affects 1 in every 3500 boys resulting in progressive muscle atrophy, loss of ambulation and cardio-respiratory failure ([@bib38]). In DMD patients, the leading cause of mortality is diaphragm dysfunction ([@bib2]; [@bib20]; [@bib56]). In the *mdx* animal, a mouse model of DMD, disease progression in the diaphragm mimics the human development of the disease ([@bib70]), and respiratory dysfunction has been shown to promote cardiac dysfunction ([@bib3]; [@bib2]; [@bib36]).

NADPH Oxidase 2 (Nox2) has been shown to play an important role in dystrophic muscle. Nox2 content and activity are upregulated prior to the onset of inflammation and necrosis ([@bib82]) and downregulating Nox2 ROS production protects against pathophysiological alterations in young (5--7 wk) dystrophic muscle ([@bib50]). Recent evidence indicates the microtubule (MT) network is dysregulated in dystrophic muscle ([@bib6]; [@bib28]; [@bib31]; [@bib58]), which results in aberrant Nox2 ROS production and implicates Nox2 ROS in altered mechanotransduction ([@bib31]). However, Nox2 ROS is upregulated early (19 d; ([@bib82])), prior to changes in the MT network ([@bib6]; [@bib28]; [@bib31]; [@bib58]), and oxidation has been shown to be a post-translational modification of the MT network ([@bib11]; [@bib35]; [@bib83]). These findings raise the question of whether Nox2 ROS initiates changes in the MT network.

In addition to increased Nox2 ROS production and alterations in the MT network, dystrophic muscle is characterized by increased fibrosis and muscle stiffness ([@bib14]; [@bib15]; [@bib75]). The de-tyrosination of α-tubulin (DT-tubulin) has been proposed as a mechanism which prevents the de-polymerization of the MT network, causing an increase in muscle stiffness and dysfunction in isolated muscle cells ([@bib30]; [@bib66]). However, Ervasti and colleagues ([@bib6]) demonstrated increased muscle stiffness with no differences in relative DT-tubulin amounts between *mdx* and WT mice. MT formation is also sensitive to the extracellular environment ([@bib48]; [@bib60]; [@bib61]) and increased extracellular matrix (ECM) has been implicated in increased muscle stiffness and decreased force production ([@bib17]; [@bib45]; [@bib56]; [@bib67]; [@bib85]). Intriguingly, transgenic *mdx* mice expressing either a nearly full length dystrophin (Dys^Δ71-78^-*mdx*) or overexpressing utrophin (*Fiona*) suggest that MT density and organization is independent of the level of MT de-tyrosination ([@bib5]; [@bib6]). Taken together, the role of de-tyrosinated MTs in tissue stiffness and disease pathogenesis in muscular dystrophy is unclear.

Skeletal muscle stiffness traditionally has been evaluated using either atomic force microscopy (AFM; \[[@bib9]; [@bib30]; [@bib42]; [@bib73]\]) or the passive properties of muscle measured during stretch ([@bib22]; [@bib23]; [@bib41]; [@bib67]). AFM evaluates single muscle fiber stiffness but does not consider cell-cell interactions or the influence of the extra cellular matrix. While evaluating stiffness through muscle passive properties considers the series and parallel elastic components together it does not differentiate between the contributions of longitudinal (series) or transverse (parallel) tissue stiffness within overall muscle stiffness. Optical coherence elastography (OCE) recently has been developed as a unique method to noninvasively evaluate tissue stiffness ([@bib37]; [@bib77]; [@bib78]; [@bib79]). Here, we utilize OCE to evaluate the differences in longitudinal and transverse tissue stiffness in the diaphragm of *mdx* mice. Previous data indicate *mdx* muscle is compromised in the transverse direction ([@bib34]; [@bib64]). Therefore, OCE may provide a unique method to differentiate pathological alterations in longitudinal and transverse stiffness and their impact on muscle function.

Because the altered MT network and fibrosis develop later in the disease pathology, after Nox2 ROS production has been initiated, we hypothesized that genetically eliminating Nox2 ROS production would prevent alterations to the MT network and reduce diaphragm stiffness thereby improving muscle and respiratory function in adult *mdx* mice. We also hypothesized, at the tissue level, stiffness would be greater in the transverse direction and fibrosis would be the major determinant of tissue stiffness.

Results {#s2}
=======

Genetic deletion of Nox2 ROS production prevents disorganization of the microtubule network in dystrophic muscle {#s2-1}
----------------------------------------------------------------------------------------------------------------

Previous data have shown that tubulin content is upregulated in muscular dystrophy, and DT-tubulin may influence MT stability ([@bib30]; [@bib31]; [@bib58]). However, [@bib6] have suggested that the relative DT-tubulin level is not elevated in *mdx* muscle. Our data confirm that α-, β-, and DT-tubulin are elevated with muscular dystrophy and extend these findings to show that eliminating Nox2 ROS production in *mdx* mice prevents the increase in all three forms of tubulin ([Figure 1B--D](#fig1){ref-type="fig"}). Because DT-tubulin is the de-tyrosinated form of α-tubulin, and both DT- and α-tubulin are elevated in *mdx* muscle, we assessed the fraction of α-tubulin that is de-tyrosinated. We found that there is no difference in the DT-/α-tubulin ratio between groups ([Figure 1E](#fig1){ref-type="fig"}), suggesting that the increase in DT-tubulin is likely due to increased α-tubulin. [@bib31] demonstrated Nox2 ROS production is increased in response to a polymerized MT network. We found that Nox2 ROS production leads to increased MT disorganization ([Figure 1G--H](#fig1){ref-type="fig"}) and density ([Figure 1I](#fig1){ref-type="fig"}) in dystrophic diaphragm muscle which was prevented by eliminating Nox2 ROS. These results indicate that Nox2-generated ROS increases tubulin content, MT disorganization and MT polymerization in dystrophic diaphragm muscle and questions the role of DT-tubulin in MT stabilization or density.

![Eliminating Nox 2 ROS production prevents alterations in tubulin content and the microtubule network.\
(**A**) Representative western blot images of α-, β-, and DT-tubulin content in all three genotypes. (**B--D**) Eliminating Nox2 ROS production decreases absolute α-, β- and DT-tubulin content in dystrophic diaphragm muscle. (**E**) The relative amount of DT-/α-tubulin is not different between groups. (**F**) Representative images of diaphragm myofibers stained with α-tubulin. (**G--I**) The lack of Nox 2 ROS prevents microtubule disorganization and the increase in microtubule density seen in *mdx* muscle. p≤0.05 \*Significant difference between groups in at least (**A--E**) n~animals~ = 6 and (**F--I**) n~animals~ = 3 and n~fibers~ = 15.](elife-31732-fig1){#fig1}

Genetic inhibition of Nox2 ROS decreases skeletal muscle fibrosis {#s2-2}
-----------------------------------------------------------------

Increased fibrosis is a pathological hallmark of muscular dystrophy. In accordance with previous studies, we observed increased diaphragm fibrosis in *mdx* compared with WT mice ([Figure 2](#fig2){ref-type="fig"}). Eliminating Nox2 ROS in dystrophic muscle resulted in reduced collagen as measured by Trichrome staining ([Figure 2A](#fig2){ref-type="fig"}), hydroxyproline concentration([Figure 2B](#fig2){ref-type="fig"}), and collagen I content ([Figure 2C](#fig2){ref-type="fig"}) as well as fibronectin content ([Figure 2C](#fig2){ref-type="fig"}). These data suggest that decreasing Nox2 ROS results in a significant decrease in fibrosis in the *mdx* diaphragm.

![Genetic deletion of Nox2 ROS production reduced fibrosis.\
(**A**) Representative trichrome images of fibrosis in all three genotypes. Eliminating Nox2 ROS production in dystrophic muscle reduced fibrosis compared with *mdx* mice. (**B**) Hydroxyproline levels were elevated in dystrophic muscle and eliminating Nox2 ROS reduced hydroxyproline content compared with *mdx* mice. (**C**) Representative western blot images for fibronectin and collagen I content in all three genotypes. Fibronectin and collagen I content were elevated in *mdx* diaphragm and eliminating Nox2 ROS reduced both toward WT levels. p≤0.05 \* Significant difference between groups in at least n~animals~ = 6 for trichrome and hydroxyproline and n~animals~ = 3 for fibronectin and collagen I.](elife-31732-fig2){#fig2}

Muscle stiffness and stretch induced ROS are reduced in Nox2 deficient dystrophic muscle {#s2-3}
----------------------------------------------------------------------------------------

Microtubules have been shown to be sensitive to the extracellular environment ([@bib48]; [@bib60]; [@bib61]) and cell-to-cell (transverse) interactions are critical in skeletal muscle force transduction ([@bib51]; [@bib59]; [@bib64]). We evaluated the role of Nox2 ROS in diaphragm mechanical properties using two distinct methods: passive stretch to evaluate the series and parallel elastic components together and optical coherence elastography (OCE) to differentiate between the contributions of series (longitudinal stiffness) and parallel (transverse stiffness) components within overall muscle tissue stiffness. [Figure 3A and E](#fig3){ref-type="fig"} demonstrate the system design for both passive stretch and OCE, respectively, [Figure 3F](#fig3){ref-type="fig"} shows a sample OCT image of the diaphragm and [Figure 3---video 1](#fig3video1){ref-type="video"} illustrates a sample wave propagation taken during OCE. Passive stiffness while lengthening the diaphragm to 120% L~o~ was increased in *mdx* compared with WT mice, and eliminating Nox2 ROS resulted in reduced tissue stiffness compared with *mdx* diaphragm ([Figure 3B--C](#fig3){ref-type="fig"}). Transverse and longitudinal stiffness, using OCE, was increased in diaphragm of *mdx* mice compared with WT mice. Interestingly, eliminating Nox2 ROS production reduced only longitudinal stiffness in *Ncf1*^-/-^::*mdx* (designated as p47^(-/-)^/*mdx*) mice to WT levels ([Figure 3G--H](#fig3){ref-type="fig"}). Muscle function was measured pre- and post-OCE to ensure OCE measurements did not compromise tissue health. Muscle function for all genotypes was not altered following OCE measurements ([Figure 3I](#fig3){ref-type="fig"}). We also found that stretch induced ROS was elevated in *mdx* diaphragm compared with both WT and p47^(-/-)^/*mdx* diaphragm tissue ([Figure 3D](#fig3){ref-type="fig"}). These data suggest that elevated Nox2 ROS increases diaphragm stiffness in dystrophic muscle and demonstrate Nox2 as the source of stretch induced ROS at the tissue level. In addition, stiffness measured using OCE can detect changes in tissue elastic properties based on fiber orientation and indicate a direction-dependent response to alterations in tissue stiffness.

![The lack of Nox2 ROS reduces muscle stiffness and stretch-induced ROS.\
(**A**) Image of the passive stretch experimental set-up. (**B**) Average passive diaphragm force recorded during stretch for each genotype. (**C**) Eliminating Nox2 ROS production reduced diaphragm tissue stiffness. (**D**) Stretch induced ROS in *mdx* muscle was elevated above WT levels and eliminated in p47^-/-^/*mdx* diaphragm. (**E**) Image of the OCE experimental set-up. (**F**) Representative OCT image of the diaphragm taken prior to OCE experiments. (**G**) Transverse diaphragm muscle stiffness increased in *mdx* compared with WT mice; eliminating Nox2 ROS resulted in a decrease toward WT (p=0.09). (**H**) Genetic inhibition of Nox2 ROS reduced longitudinal diaphragm stiffness to WT values. (**I**) Muscle function was not altered following OCE measurements. p≤0.05 \*Significant difference between groups in at least n~animals~ = 6 per group.](elife-31732-fig3){#fig3}

Fibrosis is a major determinant of diaphragm stiffness {#s2-4}
------------------------------------------------------

Increased DT-tubulin has been suggested to stabilize the microtubule network resulting in less dynamic microtubules thereby increasing tissue stiffness ([@bib30]; [@bib66]). Our results demonstrate that while both α- and DT-tubulin are upregulated in dystrophic muscle the ratio of DT- to α-tubulin revealed no significant difference between groups ([Figure 1E](#fig1){ref-type="fig"}). A linear regression analysis demonstrated that fibrosis, DT-tubulin and α-tubulin significantly correlate to transverse and longitudinal diaphragm stiffness while the DT-/α-tubulin ratio only demonstrated a significant correlation with longitudinal stiffness ([Table 1](#table1){ref-type="table"}). A multiple linear regression analysis with either DT- or DT-/α-tubulin ratio and fibrosis revealed that the variance was no different than fibrosis alone ([Table 1](#table1){ref-type="table"}). Fibrosis accounted for 45% of the variance in the longitudinal and nearly 70% in the transverse direction. These data indicate that while tubulin content correlates with muscle stiffness, fibrosis accounts for the majority of the variance in muscle stiffness at the tissue level.

10.7554/eLife.31732.006

###### Tubulin and stiffness correlations.

  Adj R^2^       Fibrosis   α-tubulin   β-tubulin   DT-tubulin   DT-/α-tubulin   MLR (fibrosis/DT)   MLR (fibrosis/ratio)
  -------------- ---------- ----------- ----------- ------------ --------------- ------------------- ----------------------
  Transverse     0.69 \*    0.46 \*     0.51 \*     0.51 \*      0.10            0.69                0.67
  Longitudinal   0.44 \*    0.20 \*     0.40 \*     0.41 \*      0.19 \*         0.44                0.49

Most variables significantly correlated with both transverse and longitudinal stiffness. MLR revealed fibrosis accounted for the majority of the variance observed in either stiffness measure. p≤0.05 \*Significant correlation in at least nanimals = 6.

Eliminating Nox2 ROS improves diaphragm muscle and respiratory function {#s2-5}
-----------------------------------------------------------------------

Diaphragm muscle and respiratory function are compromised in *mdx* mice ([@bib24]; [@bib27]; [@bib50]; [@bib56]). We previously have shown that eliminating Nox2 ROS production protected against diaphragm alterations in young (4--6 wks) *mdx* mice ([@bib50]). Given muscle dysfunction in dystrophy is progressive, we wanted to determine whether eliminating Nox2 ROS provided protection against muscle/diaphragm dysfunction in older dystrophic mice. Here, we show that diaphragm function is impaired in adult (16--24 wks) *mdx* muscle and eliminating Nox2 ROS partially protected against the force deficits ([Figure 4A](#fig4){ref-type="fig"}). Eliminating Nox2 ROS in adult dystrophic muscle also protected against alterations in diaphragm fiber cross sectional area, fiber type and central nuclei [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). These results, in combination with our previous data ([@bib50]), indicate the lack of Nox2 ROS provides protection against pathophysiological alterations observed in dystrophic diaphragm muscle at different stages of disease pathology. In addition, eliminating Nox2 ROS protected against decrements in respiratory rate (f), minute ventilation (Mv), and peak inspiratory flow (PIF) in adult *mdx* mice ([Table 3](#table3){ref-type="table"}). A linear regression analysis demonstrated that fibrosis ([Figure 4B](#fig4){ref-type="fig"}) and both transverse and longitudinal diaphragm stiffness ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}) significantly correlated with peak diaphragm force. A multiple linear regression analysis revealed when either transverse or longitudinal diaphragm stiffness was included with fibrosis, the variance was no different than fibrosis alone ([Table 2](#table2){ref-type="table"}). These data indicate Nox2-derived ROS drive alterations in *mdx* diaphragm which lead to diaphragm and respiratory dysfunction.

![Eliminating Nox2 ROS protects against muscle and respiratory dysfunction.\
(**A**) WT was significantly different from *mdx* and p47^-/-^/*mdx* animals at all stimulation frequencies. The p47^-/-^/*mdx* animals were different from *mdx* at 60--100 Hz and trended toward significance at 40 Hz (p=0.098). (**B**) Fibrosis significantly correlated with muscle force. p≤0.05 \*Significant difference between groups in at least n~animals~ = 6.](elife-31732-fig4){#fig4}

10.7554/eLife.31732.010

###### Force and stiffness correlations

  Adj R^2^   Fibrosis   MLR (fibrosis/trans)   MLR (fibrosis/long)   MLR (fibrosis/long/trans)
  ---------- ---------- ---------------------- --------------------- ---------------------------
  Force      0.57       0.52                   0.52                  0.49

MLR revealed fibrosis accounted for a majority of the variance observed in diaphragm muscle function. p≤0.05 \*Significant difference between groups in at least nanimals = 6.

10.7554/eLife.31732.011

###### Respiratory function.

                   WT                 *mdx*           p47^-/-^/*mdx*
  ---------------- ------------------ --------------- ------------------
  f (breath/min)   408.2 ± 14.5 \*    279.8 ± 18.3    377.3 ± 17.0 \*
  T~v~ (ml)        0.25 ± 0.009       0.24 ± 0.008    0.26 ± 0.012
  M~v~ (ml)        100.3 ± 5.6 \*     65.9 ± 17.6     99.2 ± 8.6 \*
  PIF (ml/s)       7.6 ± 0.30 \*      5.9 ± 0.56      8.0 ± 0.51 \*
  PEF (ml/s)       4.2 ± 0.25         3.2 ± 0.24      4.4 ± 0.39 \*
  T~i~ (s)         0.057 ± 0.002 \*   0.080 ± 0.007   0.057 ± 0.002 \*
  T~e~ (s)         0.129 ± 0.009 \*   0.190 ± 0.012   0.138 ± 0.008 \*

Dystrophic mice lacking Nox 2 ROS production maintained respiratory function similar to WT levels. p≤0.05 \*Significant difference vs. *mdx* in at least nanimals = 9.

Taxol-induced MT polymerization has no effect on tissue stiffness but induced ROS production {#s2-6}
--------------------------------------------------------------------------------------------

To further elucidate the role of the MT network in tissue stiffness and ROS production, we incubated WT diaphragm with Taxol to polymerize the MT network. We observed similar alterations in the MT network between Taxol-treated WT and *mdx* animals ([Figure 1F--I](#fig1){ref-type="fig"}; [Figure 5A--D](#fig5){ref-type="fig"}). Taxol increased MT density ([Figure 5D](#fig5){ref-type="fig"}) and resulted in disorganization of the MT network ([Figure 5B--C](#fig5){ref-type="fig"}). There was no difference in passive stiffness between Taxol and DMSO-treated diaphragm tissue ([Figure 5E--F](#fig5){ref-type="fig"}); however, there was a difference in stretch-induced ROS production ([Figure 5G](#fig5){ref-type="fig"}). These data, in combination with our previous data, support the idea that while alterations in the MT network increase ROS production, increases in DT-tubulin, MT density or MT disorganization do not influence tissue stiffness.

![Taxol-induced MT polymerization has no effect on tissue stiffness but induced ROS production.\
(**A**) Representative images of MT network in control (DMSO) and Taxol-treated diaphragm (20 μM for 2 hr). (**B--D**) Taxol induced MT disorganization and increased microtubule density compared with control. (**E**) Average passive diaphragm force recorded during stretch was not affected by Taxol. (**F**) Polymerizing the MT network had no effect on diaphragm tissue stiffness. (**G**) MT network polymerization enhanced stretch-induced ROS in Taxol-treated diaphragm. p≤0.05 \*Significant difference between groups in at least (**A--D**) n~animals~ = 3 and n~fibers~ = 15 and (**E--G**) n~animals~ = 5.](elife-31732-fig5){#fig5}

Discussion {#s3}
==========

Froehner and colleagues ([@bib55]) originally demonstrated MT disorganization in dystrophic muscle and its subsequent restoration with the re-introduction of mini-dystrophin. In *mdx* mice, the MT network becomes altered at approximately 7--8 wks of age ([@bib58]) and remains altered with age (9--11 months) ([@bib30]). It has been suggested that alterations in the MT network lead to increased Nox2 ROS production and altered mechanotransduction in adult *mdx* muscle ([@bib30]; [@bib31]). However, Nox2 ROS is upregulated prior to changes in the MT network ([@bib30]; [@bib58]; [@bib82]), raising the question whether increased Nox2 ROS drives changes in the MT network. In neurons, tubulin oxidation prevents MT polymerization ([@bib11]; [@bib35]; [@bib83]); however, it is unclear what role increased ROS production plays in modulating the MT network of skeletal muscle. Our data show that diaphragm MT alterations are increased in adult dystrophic muscle and eliminating Nox2 ROS prevented the increase in α-, β-, and DT-tubulin content ([Figure 1B--D](#fig1){ref-type="fig"}), MT density ([Figure 1I](#fig1){ref-type="fig"}), MT disorganization ([Figure 1G--H](#fig1){ref-type="fig"}) and stiffness ([Figure 3C,G--H](#fig3){ref-type="fig"}) observed in *mdx* mice. The MT network can be affected by muscle fiber type and regeneration ([@bib55]; [@bib62]; [@bib63]); both of which are altered in dystrophic muscle. Here, we show that eliminating Nox2 ROS protected against alterations in fiber type switching and reduced central nuclei in dystrophic muscle. These data indicate Nox2 ROS, either directly or indirectly through alterations in fiber type or regeneration, is modulating the MT network.

Previous work has focused on either the cortical ([@bib55]; [@bib58] ) or some undetermined combination of the cortical and intermyofibrillar MT network ([@bib30]; [@bib31] ). However, given the intermyofibrillar MT network surrounds the contractile apparatus, any alterations to this network likely affect force production. In addition, Nox2 is located in the plasma membrane and 60--90% of the plasma membrane in skeletal muscle is comprised by the t-tubules ([@bib19]; [@bib46]; [@bib54]). Therefore, the intermyofibrillar MT network may contribute more to muscle function and the mechanical activation of Nox2 ROS compared with the cortical MT network. To further explore whether the altered intermyofibrillar MT network influenced diaphragm stiffness and ROS production, we incubated WT diaphragm with Taxol. Polymerizing the MT network with Taxol resulted in increased intermyofibrillar MT density ([Figure 5D](#fig5){ref-type="fig"}) and disorganization ([Figure 5B--C](#fig5){ref-type="fig"}), similar to the diaphragm from *mdx* mice, but no change in tissue stiffness was detected. We found that Taxol increased stretch-dependent ROS production at the tissue level ([Figure 5F](#fig5){ref-type="fig"}); similar to what Khairallah et al. has shown in single FDB fibers ([@bib31]). Taken together, we show that Nox2 ROS is an early event that modulates the MT network, potentially resulting in a feed forward mechanism where elevated Nox2 ROS production increases MT density and disorganization which in turn leads to additional Nox2 ROS production. We currently are investigating the mechanisms by which Nox2 ROS modulates the MT network.

Respiratory insufficiency in the DMD patient is caused by respiratory muscle weakness, leading to impaired ventilation through an inability to inhale and exhale fully, ultimately resulting in a need for mechanical ventilation. Dystrophic muscle is characterized by increased fibrosis and while some show no link between altered collagen and stiffness ([@bib10]; [@bib69]) others have implicated fibrosis in decreased function and stiffness ([@bib8]; [@bib17]; [@bib27]; [@bib43]; [@bib45]; [@bib56]; [@bib67]; [@bib85]). Lateral force transmission through the endomysial layer of skeletal muscle has been shown to be important in overall force production ([@bib51]; [@bib52]; [@bib59]; [@bib71]) and, in *mdx* mice, force is compromised in the transverse direction ([@bib34]; [@bib64]). The endomysial layer also has increased levels of fibrosis which affects force production and correlates with the age of loss of ambulation in dystrophic muscle ([@bib16]; [@bib17]). Here, we show decreased diaphragm muscle ([Figure 4A](#fig4){ref-type="fig"}) and respiratory function ([Table 3](#table3){ref-type="table"}) and increased fibrosis ([Figure 2B](#fig2){ref-type="fig"}) and tissue stiffness ([Figure 3C,G--H](#fig3){ref-type="fig"}) in dystrophic muscle. Eliminating Nox2 ROS in dystrophic diaphragm muscle reduced fibrosis and tissue stiffness, increased force and prevented the decline in respiratory function. Highlighting the importance of cell-cell interactions, our data demonstrate a stronger correlation between force and transverse stiffness ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}) and fibrosis and transverse stiffness than longitudinal stiffness ([Table 1](#table1){ref-type="table"}). These data indicate that fibrosis is a crucial factor altering tissue stiffness and force production resulting in impaired cell-cell interactions. Furthermore, a 26% increase in diaphragm force maintained respiratory function in the p47^-/-^/*mdx* mouse, likely decreasing the need to place patients on a ventilator.

Several therapeutics designed to reduce fibrosis have proved beneficial in improving muscle function in dystrophic muscle ([@bib8]; [@bib25]; [@bib56]; [@bib72]; [@bib81]). Therefore, based on our data, it is conceivable that decreased fibrosis reduces transverse muscle stiffness, improving lateral force transmission and thereby overall muscle function. In addition, it has been suggested that fibrosis induces a feed forward loop causing collagen producing myogenic cells not to differentiate into terminal satellite cells; inhibiting myogenesis and enhancing fibrosis ([@bib1]). These data are supported by the idea that progenitor cells take on a fibrogenic-like phenotype with aging; resulting in the loss of regenerative capacity in dystrophic muscle ([@bib7]; [@bib57]). The reduction in fibrosis observed by eliminating Nox2 ROS in dystrophic muscle may implicate a role for improved satellite cell activity given the reduced central nuclei and the increased CSA and Type 2B fibers ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}) observed in the p47^-/-^/*mdx* mice. In addition, we previously demonstrated eliminating Nox2 ROS improves autophagy in dystrophic muscle ([@bib50]) and autophagy is necessary for satellite cell differentiation and fusion ([@bib21]). Future experiments are needed to investigate the role of Nox2 ROS in the impairment of satellite cell function

Tissue stiffness in leg muscle mirrors changes in the MT network; becoming altered in *mdx* animals at approximately 7--8 weeks of age ([@bib84]) and remaining elevated in older animals ([@bib23]). Skeletal muscle stiffness has predominantly been assessed using atomic force microscopy (AFM) on single fibers ([@bib9]; [@bib30]; [@bib42]; [@bib73]) or by passively lengthening muscle tissue ([@bib22]; [@bib23]; [@bib41]; [@bib67]). In C2C12 cells and isolated adult myofibers, alterations to the MT network increased cell stiffness, measured via AFM, and altered mechanotransduction ([@bib30]; [@bib31]). However, AFM uses a point specific bending moment evaluating only the near-membrane mechanical properties at that point ([@bib30]). While this approach is vital for understanding intracellular contributions to single-cell signaling and near-membrane mechanics, it does not consider the ECM or cell-cell interactions in overall tissue mechanotransduction. Passive stretch takes into consideration both of these factors; however, it evaluates both the series (longitudinal) and parallel (transverse) elastic components together, making it difficult to assess the individual contributions to overall tissue stiffness. To address these limitations, we used two techniques to evaluate tissue stiffness, passive stretch and OCE. Interestingly, eliminating Nox2 ROS production partially prevented increases in tissue stiffness during passive lengthening ([Figure 3C](#fig3){ref-type="fig"}) similar to transverse stiffness measured using OCE ([Figure 3G](#fig3){ref-type="fig"}). In addition, we demonstrate a partial protection against force decrement ([Figure 4A](#fig4){ref-type="fig"}) and elevated transverse stiffness by eliminating Nox2 ROS production in the diaphragm ([Figure 3G](#fig3){ref-type="fig"}). These data highlight the importance of lateral (transverse) force transmission, and the significance of transverse stiffness in force production.

In isolated muscle cells, DT-tubulin, the de-tyrosinated form of α-tubulin, has been suggested to stabilize the MT network resulting in increased stiffness and reduced force ([@bib30]; [@bib66]). However, MT formation is sensitive to alterations in the extracellular environment ([@bib48]; [@bib60]; [@bib61]) implicating fibrosis in altering tissue stiffness. Previous work in neurons ([@bib4]; [@bib13]; [@bib26]; [@bib32]; [@bib47]; [@bib68]; [@bib80]) indicates DT-tubulin simply occurs temporally at the same time but was not the cause of MT stabilization. Furthermore, in skeletal muscle [@bib6] have recently demonstrated that while DT-tubulin was elevated in *mdx* quadriceps muscle, the fraction of DT-/α-tubulin was no different than WT mice. Our data support the idea that while DT-tubulin is elevated in dystrophic diaphragm the DT-/α-tubulin ratio is no different ([Figure 1E](#fig1){ref-type="fig"}), indicating elevated DT-tubulin is a function of elevated α-tubulin and not the cause of stabilized MTs. Using the DT-/α-tubulin ratio as the indicator of stabilized MTs, our data demonstrate a significant but weak correlation with OCE longitudinal diaphragm stiffness and no correlation with transverse stiffness ([Table 1](#table1){ref-type="table"}). When included with fibrosis, while elevated DT-tubulin and the DT-/α-tubulin ratio correlated with tissue stiffness, MLR revealed neither influenced diaphragm tissue stiffness above fibrosis. These data suggest neither the absolute nor the relative amount of DT-tubulin influence tissue stiffness and fibrosis is the main determinant of diaphragm tissue stiffness.

Nox2 protein level and ROS production are upregulated early in dystrophic muscle prior to the inflammatory response ([@bib50]; [@bib82]). Previously, we have shown that Nox2 ROS production initiates a feed forward loop exacerbating Nox2 ROS production and inhibiting autophagic flux through activation of Src kinase ([@bib50]). Interestingly, recent data by Froehner and colleagues ([@bib81]) have shown that simvastatin reduced Nox2 protein levels, oxidative stress and fibrosis in *mdx* mice. Here we provide evidence for an additional feedforward mechanism where Nox2 ROS alters the MT network, which in turn exacerbates Nox2 ROS production. We also demonstrate that eliminating Nox2 ROS production alleviates many of the pathophysiological alterations, such as fibrosis, which occur in dystrophic diaphragm muscle. Taken together, there is compelling evidence that Nox2 ROS production is a central event in exacerbating disease pathology, implicating Nox2 as a viable therapeutic target in muscular dystrophy.

Materials and methods {#s4}
=====================

Animals {#s4-1}
-------

C57Bl/6J (WT) and C57Bl/10ScSn-Dmd*mdx*/J (*mdx*) were purchased from Jackson Laboratories (Bar Harbor, ME) and bred following their breeding strategy. Mice lacking p47^phox^ (B6(Cg)-Ncf1m1J/J, JaxMice) were crossed with *mdx* mice to generate *Ncf1*^-/-^::*mdx* (p47 ^(-/-)^/*mdx*) mice ([@bib50])). At approximately 5 months of age and in accordance with National Institutes of Health guidelines and approved by the Institutional Animal Care and Use Committee of Baylor College of Medicine, mice were anesthetized by isoflurane (2%) inhalation and euthanized by rapid cervical dislocation followed by thoracotomy.

Diaphragm passive stretch {#s4-2}
-------------------------

Diaphragm muscle was surgically dissected and sectioned into diaphragm strips with the rib end attached to a fixed hook and the other to the lever arm of a dual-mode lever system (305C-LR-FP; Aurora Scientific Inc., Aurora, ON, Canada) using silk suture (4-0). The diaphragm was placed in a physiological saline solution containing (in mM): 2.0 CaCl2, 120.0 NaCl, 4.0 KCl, 1.0 MgSO4, 25.0 NaHCO3, 1.0 KH2PO4, 10.0 glucose, pH 7.3 and continuously gassed with 95% O2--5% CO~2~ at 25°C. Muscle length was adjusted to elicit maximum twitch force (optimal length, L~o~). A hand-held electronic caliper was used to measure L~o~ and the lever arm was programmed to passively stretch the diaphragm strip to 120% of L~o~ at 1 L~o~/s for 5 min. At the end of the stretch protocol fiber bundles were removed from the rib, trimmed of excess connective tissue, blotted dry, and weighed. Muscle weight and L~o~ were used to estimate absolute forces expressed as N/cm^2^ ([@bib12]).

To determine tissue stiffness, the Veronda-Westman model ([@bib74]) was employed to quantify Young's modulus for the first stretch. The Veronda-Westman model describes a nonlinear relationship between stress and strain and previously has been utilized to study the elasticity of a number of biological tissues, such as breast and skin ([@bib33]; [@bib74]). Assuming the diaphragm tissue as an incompressible Veronda-Westman material, under uniaxial tension, the axial stress σ is related to the resulted stretch λ through [equation 1](#equ1){ref-type="disp-formula"}: ([@bib49]; [@bib53])$$\sigma = \ \frac{2E}{3}\left( {\lambda^{2} - \frac{1}{\lambda}} \right)\left( {e^{\gamma{({\lambda^{2} + \frac{2}{\lambda} - 3})}} - \frac{1}{2\lambda}} \right),$$where λ = 1 + *ε* (*ε* is the strain), *Ε* is the Young's modulus of the diaphragm tissue at zero strain and γ is a nonlinear parameter representing the exponential increase rate of the Young's modulus over the increase of strain. Young's modulus was calculated through fitting the experimental data with [Equation 1](#equ1){ref-type="disp-formula"} in Matlab (MathWorks; Natick, MA).

ROS measurements {#s4-3}
----------------

Diaphragm intracellular ROS was measured using 6-carboxy-2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) (Invitrogen, Carlsbad, CA). Prior to stretch, the diaphragm was incubated with DCFH-DA for 30 min, washed using the physiological saline solution and de-esterified for an additional 30 min at 25°C. All cell-loading and imaging was performed in the dark to prevent light-induced oxidation of DCFH-DA. A Sutter Lamda DG-5 Ultra high-speed wavelength switcher was used to excite DCF at 470/20 nm and emission intensity was collected at 535/48 nm on a charge coupled device (CCD) Camera (CoolSNAP MYO, Photometrics, Tucson, AZ) attached to an Axio Observer (Zeiss) inverted microscope (20 × objective, 0.5 NA) at a rate of 0.2 Hz. Alterations in the rate of ROS production were baseline corrected and calculated over the final minute of the stretch period.

Effect of taxol on tissue stiffness and ROS production {#s4-4}
------------------------------------------------------

WT diaphragm tissue was incubated with 20 μM Taxol (Sigma-Aldrich, St. Louis, MO) or DMSO (Sigma-Aldrich, St. Louis, MO) control for 2 hr at RT. After 1 hr, the tissue was incubated with DCFH-DA, de-esterified and passively stretched as described above.

Optical coherence elastography {#s4-5}
------------------------------

Optical coherence elastography (OCE) is a novel technique for nondestructive assessment of mechanical properties of tissues ([@bib29]; [@bib37]). The principle of OCE is based on producing a pressure wave on the sample and monitoring the propagation of the wave using phase-sensitive optical coherence tomography (OCT) imaging on nanometer scale. The velocity of the wave propagation in different directions along the surface is used to deduct tissue elasticity anisotropically ([@bib39]; [@bib78]). A home-built OCE system was utilized which contains a focused air-puff device for tissue stimulation ([@bib76]) and a spectral-domain OCT system to capture the tissue mechanical response ([@bib79]). The air-puff system provided a highly localized (\~150 µm in diameter), short-duration (\~1 ms), and low-pressure (below 10 Pa) air stream to stimulate the surface of the diaphragm tissue in a noncontact fashion. The induced tissue displacement had a micro-scale amplitude. The OCT system had an axial resolution of \~5 µm in tissue, an imaging beam diameter of \~4 µm at the focal plane, and a displacement sensitivity of \~11 nm with the phase of the OCT complex signal. The tissue displacement over time was detected using the temporal phase profile from the OCT system. A previously reported shear wave imaging OCT approach (Wang and Larin) was utilized to capture the elastic wave propagation in a depth-resolved 2D field of view with a time resolution of 16 µs. Cross-correlation of tissue displacement profiles was used to measure the time delay formed by the wave propagation at different locations. The elastic wave velocity was thus quantified based on the slope from a linear fit of the time delay with respect to the wave propagation distance. A surface wave model ([@bib18]) that relates the sample Young's modulus *Ε* to the wave velocity *C* was utilized to estimate the tissue elasticity through [Equation 2](#equ2){ref-type="disp-formula"}: ([@bib39]; [@bib78])$$E = \frac{2\rho \times \left( {1 + \nu} \right)^{3} \times C^{2}}{\left( {0.87 + 1.12\nu} \right)^{2}}$$where *ρ* is the tissue density and *ν* is the Poisson's ratio; diaphragm density was 1060 kg/m^3^ ([@bib44]). Due to the nearly incompressibility of soft tissue, the Poisson's ratio of 0.5 was utilized ([@bib42]). The averaged wave velocity value from 0 to 0.1 mm depth range from the tissue surface was used for calculation of the Young's modulus. For each diaphragm sample, the elastic wave assessment was conducted in the transverse and longitudinal directions of the muscle fiber.

Ex vivo force measurements {#s4-6}
--------------------------

Diaphragm muscle was surgically dissected from mice and sectioned into diaphragm strips with one end attached to a fixed hook and the other to a force transducer (F30, Harvard Apparatus) using silk suture (4-0) in a physiological saline solution continuously gassed with 95% O~2~--5% CO~2~ at 25°C. Diaphragm strips were incubated at 25°C for 10 min and optimal muscle length (L~o~) and voltage (V~max~) were adjusted to elicit maximum twitch force. Following a 5-min rest period, the diaphragm strip was stimulated at 150 Hz with pulse and train durations of 0.5 and 250 ms, respectively. Immediately after stimulation, L~o~ was determined using a hand-held electronic caliper and the diaphragm strip was placed at L~o~ in a 100 × 15 mm petri dish (VWR, Radnor, PA) for OCE measurements. Following OCE, the diaphragm was re-suspended from the force transducer at L~o~ and after a 5-min rest period stimulated again at 150 Hz to ensure OCE measurements did not compromise the diaphragms functional properties.

To determine the force-frequency relationship, diaphragm strips were incubated at 30°C for 15 min and L~o~ and V~max~ were adjusted to elicit maximum twitch force. Following a 5-min rest period, force-frequency characteristics were measured at stimulation frequencies of 1, 5, 10, 20, 40, 60, 80, and 100 Hz every minute with pulse and train durations of 0.5 and 250 ms. At the end of the contractile protocol, L~o~ was measured using a hand-held electronic caliper. Following both stimulation protocols, fiber bundles were trimmed of excess bone and connective tissue, blotted dry, and weighed. Muscle weight and L~o~ were used to estimate cross-sectional area and absolute forces expressed as N/cm^2^ (Close).

Unrestrained whole-body plethysmography {#s4-7}
---------------------------------------

Respiratory function was monitored in unrestrained mice using Buxco small animal whole-body plethysmography (Data Sciences International, New Brighton, MN) and FinePointe software (Data Sciences International, New Brighton, MN). The system was calibrated each day prior to data collection. On the day of data collection, animals were placed in individual chambers and given 30 min to acclimate; followed by 60 min of data collection. The software averaged the data over each minute and recorded a value every minute for 60 min. To ensure data was representative, breath frequency was used to ensure the mouse had not held its breath, buried its head under its body or was breathing too rapidly. Mean breath frequency was calculated and data which fell outside 1SD of the mean was excluded from the data analysis ([@bib65]).

Western blot {#s4-8}
------------

Lysates from diaphragm tissue were extracted and quantified with the bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, IL), using BSA as the standard. Lysates were separated via SDS-PAGE and transferred to polyvinyldifluoride (PVDF) membranes. All tubulin blots were incubated in blocking buffer (5%, w/v, dried skimmed milk in Tris-buffered saline, pH 7.4, and 0.2% Tween 20; TBST) for 60 min and incubated overnight with anti-α-tubulin (Santa Cruz Biotechnologies), anti-β-tubulin (Cell Signaling Technology), anti-detyrosinatedtubulin (Millipore) and anti-GAPDH (Millipore) in blocking buffer. Fibronectin and collagen blots were blocked for 60 min in blocking buffer as above except with. 05% Tween 20 and incubated with anti-fibronectin (Millipore), anti-collagen (Abcam) and anti-GAPDH for 60 min at room temperature (RT). Tubulin and fibronectin blots were exposed to IRDye Secondary Antibodies (LI-COR Biosciences) diluted in TBST for 60 min at RT and washed again. The LI-COr Odyssey Infrared Imaging System was used for blot detection and ImageJ software for blot analysis. The collagen blot was probed with secondary antibodies; ECL anti-mouse IgG HRP (NA931, GE Healthcare) and ECL Anti-rabbit IgG HRP (NA93401, GE Healthcare) for 60 min at RT. The membrane was imaged using the Chemidoc touch with Clarity and Clarity Max ECL reagent (Bio-Rad, Hercules, CA). Image analysis was performed using Biorad Image Lab 6.0 software.

Hydroxyproline assay {#s4-9}
--------------------

Diaphragm collagen content was measured using a hydroxyproline assay kit (Sigma-Aldrich, St. Louis, MO). Briefly, diaphragm tissue was homogenized and hydrolyzed in 200 µl of 6 M hydrochloric acid at 100°C for 3 hr. Hydrolysate was transferred to a 96-well plate (Corning, Corning, NY) and evaporated in an oven at 60°C. Following evaporation, the Chloromine T/Oxidation Buffer mixture was added to all wells and incubated for 5 min at RT. DMAB (4-(Dimethylamino) benzaldehyde) was diluted in a Perchloric Acid/Isopropanol solution, added to all wells, and incubated for 90 min at 60°C. A hydroxyproline standard curve (0--1.0 µg) was included in the assay to quantify hydroxyproline content in each sample. All samples, including the standard curve, were performed in duplicate and absorbance was measured at 560 nm. Results are reported as µg of hydroxyproline per mg of tissue (µg/mg).

Immunofluorescence {#s4-10}
------------------

For fiber-type, serial diaphragm sections of 12--14 µm thickness were sectioned at −24°C using a refrigerated cryostat (Shandon Cryotome E, Thermo). Sections were fixed with cold methanol for 20 min and incubated overnight in a humid box at 4°C with Anti-Type I (BA-F8) and anti-Type IIA (SC-71) antibodies purchased from Developmental Studies Hybridoma Bank (DSHB; Iowa City, IA). Sections were then incubated for 3 hr with IgG1 and IgG2b isotype-specific secondary antibodies (Invitrogen, Waltham, MA). Slides were mounted with VECTASHIELD anti-fade mounting media containing DAPI (Vector Laboratories, Berlingame, CA). Images were acquired using a CCD camera (Digital Sight DS-Fi1, Nikon) attached to an upright microscope (Nikon Eclipse 80i, 10 × objective, 0.45 NA). Images were analyzed using ImageJ software.

For α--tubulin staining, diaphragm tissue was fixed at L~o~ using 10% neutral buffered formalin (VWR, Radnor, PA) for 2 hr at room temperature. The tissue was rinsed three times and stored in PBS (ThermoScientific, Waltham, MA) plus 1 mM EDTA (Invitrogen, Waltham, MA). Diaphragm fibers were mechanically dissociated from the fixed diaphragm strip into single fibers and placed in 35-mm glass bottom culture dishes (MatTek, Ashland, MA) containing PBS plus 1 mM EDTA. Fibers were permeabilized with 0.1% Triton X-100 in PBS plus 1 mM EDTA for 10 min. After rinsing three times with PBS plus 1 mM EDTA, a blocking agent was added (0.1% saponin, 10% FBS in PBS plus 1 mM EDTA) for 1 hr at RT. Fibers were incubated with an Alexa-Fluor 488 conjugated α-tubulin antibody (Life Technologies, Waltham, MA) for 2 d at 4°C. Diaphragm fibers were washed with PBS and mounted with VECTASHIELD anti-fade mounting media containing DAPI (Vector Laboratories, Berlingame, CA) prior to microscopy. Fibers were imaged using a Zeiss LSM 780 confocal microscope (Zeiss, Oberkochen, Germany). Microtubule organization was analyzed using custom software ([@bib40]; software available through request to Dr Ralston) and microtubule density was assessed by summing 10 images from the intra-myofibrillar region of each fiber (\>3 µm from surface), converted to a binary image and quantified using ImageJ software. Images were subjected to background subtraction and contrast enhancement using Image J for figure presentation only.

Histology {#s4-11}
---------

Using a refrigerated cryostat (Shandon Cryotome E, Thermo), 12--14 μm thick serial sections were cut from the mid-belly region of the diaphragm at −24°C. Sections were stained using Masson's Trichrome for fibrosis and Hematoxylin and Eosin for cross-sectional area (CSA) and centralized nuclei. Images were acquired using a CCD camera (Digital Sight DS-Fi1, Nikon) attached to an upright microscope (Nikon Eclipse 80i, 10 × objective, 0.45 NA). Images were analyzed using ImageJ software.

Statistical analysis {#s4-12}
--------------------

Data are reported as mean ±SEM, unless otherwise specified. A 1-way ANOVA was used to measure statistical differences between groups. A two-way RM ANOVA was used to determine statistical differences between groups for the force-frequency data. For CSA, a Kruskal-Wallis ANOVA was used to determine differences between groups. Tukey's post-hoc test was used when statistical differences were identified. Linear regression and multiple linear regression models were used to determine correlations between variables. Statistical analysis was performed in Origin Pro (OriginLab Corporation, Northhampton, MA) with significance set *a priori* at p≤0.05.
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Decision letter
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Stanley C

Reviewing Editor

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"NADPH oxidase mediates microtubule alterations and diaphragm dysfunction in dystrophic mice\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom, Stanley C Froehner (Reviewer \#1), is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Vivek Malhotra as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary

Work by this group and others suggested that increased Nox2 activity contributes to dystrophic muscle pathology and weakness in murine models of Duchenne muscular dystrophy (DMD). Increased Nox2 activity may result from changes in microtubule (MT) cytoskeleton organization, which may contribute to dystrophic muscle dysfunction including tissue stiffness and redox signaling imbalance. In this study, Loehr and coworkers explore the relationship between Nox2 activity, MT organization (particularly stability), and dystrophic skeletal muscle dysfunction (stiffness, weakness) and associated respiratory dysfunction using a previously published mouse model lacking both dystrophin and Nox2 expression. Loehr and coworkers ask if loss of Nox2 ROS could also alter the MT cytoskeleton or fibrosis to affect mdx diaphragm tissue stiffness, contractility and ultimately whole organism respiratory/ ventilatory function.

They show that loss of Nox2: (1) reduced disorganization and density of the MT cytoskeleton without impacting the fraction of glu-tubulin associated with more stable MTs and stiff tissue (2) qualitatively reduced fibrotic collagen deposition in diaphragm (3). decreased dystrophic muscle stiffness and stretch-induced Nox2 ROS synthesis indicated by conventional analysis of passive stretch properties and more novel elastography technique. (4) improved diaphragm muscle function (published previously) and improved indices of respiratory function including respiratory rate, minute ventilation and peak inspiratory flow. Tubulin content correlated with tissue stiffness, fibrosis accounts for most of variance in muscle stiffness and diaphragm specific force (across a range of stimulation frequencies), which is supported by many previous studies. (5) MT polymerization with the chemotherapeutic taxol induced ROS production (not surprisingly) but did not impact tissue stiffness strengthening the argument that MT stabilization is not the primary driver of tissue stiffness. Thus they provide evidence suggesting a feed forward loop where Nox2 activity may impact MT organisation, which in turn feeds back to increase Nox2 activity thereby promoting dystrophic skeletal muscle dysfunction.

Essential revisions

All reviewers agreed that the findings described in this manuscript are important and potentially appropriate for publication. However, all reviewers agreed that a major concern needs to be addressed with additional data.

The concern is the reliance on a single histological method -- trichrome staining -- to determine levels of fibrosis. Because of the firmly established patchy nature of fibrosis in mdx diaphragms, this method is not quantitative due to high susceptibility to sampling bias. Because many statistical analyses, and ultimately major conclusions of this study, depend on the accurate quantification of fibrosis, the use of this qualitative approach substantially undermines the conclusions. At least one other more quantitative method, such as western blotting or hydroxyproline measurements -- preferably both -- is needed to increase the confidence in this result. This shouldn\'t be too onerous to perform and feasible in the time allowed for resubmission.

Citations needed

The authors should cite the following studies.

a\) The work of Whitehead et al. (PNAS 2015) showing that treatment of mdx mice with simvastatin reduces NOX2 levels, improves muscle function and reduces (and even reverses) fibrosis in the diaphragm.

b\) If the authors used the directionality software provided by Liu and Ralston, they must have received a readme file that asked for an acknowledgement in potential publications. This is not out of pure vanity, but as an indication that their software was used, not a home-made version.

c\) The first study to show aberrant MT organization in dystrophin null muscle fibers was PMID: 17714427 performed by Dr Froehner\'s lab. This study also showed that microdystrophin injection into 1 month old mdx mice is sufficient to prevent the subsequent disorganization of the MT cytoskeleton. Many groups subsequently confirmed these findings several years later.

1\) In the paper that introduced the mdx/p47KO mouse (Pal et al., 2014) there were several characterizations. Its ROS production was impressively close to that of a wt animal but other properties were not (Ca influx seemed lower than either wt or mdx). Do the authors have evidence that ROS itself is the cause of microtubule and stiffness changes in mdx? Muscle microtubule organization is fiber type-dependent (Ralston et al. 1999 and 2001) and regeneration-dependent (Percival et al. 2007, Traffic 8, 1424). Since the mdx/p47KO muscles have more type IIx/IIb fibers than mdx muscles and fewer centrally nucleated fibers, these 2 factors may well contribute to the improvement of microtubules. In Pal et al., the data obtained with the mouse were supplemented with data obtained with inhibitors of Src or of p91. Are there microtubule changes with an acute treatment with p91 peptides?

2\) Are the hindlimb muscle microtubules improved in the mdx/p47KO? Emphasis on the diaphragm, linked to mortality in DMD, is valuable. However, in Pompe Disease, a lysosomal storage disorder that affects skeletal and cardiac muscles, enzyme replacement therapy has improved cardiac function, preventing the death of children before age 2, but has not worked as well on skeletal muscles, leaving children and young adults with a longer but often miserable life.

3\) The results showing that fibrosis rather than microtubules causes increased stiffness of the mdx diaphragm are compelling, and a warning that the whole muscle needs to be considered when modeling DMD. However the data also show that microtubules would contribute in experiments such as those of Khairallah et al. (2012) that use collagenase dissociated FDB fibers which presumably are freed of the fibrotic layer.

4\) Most papers on the muscle microtubule network look at the dense layer of microtubules between the myofibrillar core and the sarcolemma (Percival et al., 2007; Prins et al., 2009; Khairallah et al., 2012 etc). Loehr et al., however, only examine the core microtubules. Given that both dystrophin and Nox2 are concentrated along the sarcolemma, why this choice? Are the results different (grid vs no-grid) if they look at the surface microtubules?

5\) Clarification of overlap between the current study and what the authors have published previously. Using this model the authors previously reported (Pal et al., 2014, Loehr et al., 2016) that loss of Nox2 improved dystrophic muscle pathology (reduced central nucleation, macrophage infiltration, diaphragm weakness across a range of stimulation frequencies and normalized fiber type composition). Very similar data found in Pal et al., 2014 appears again in this study in [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}. The authors do state that\"... eliminating Nox2 ROS production in young mdx mice can protect against diaphragm alterations (Pal et al., 2014).\" But is it necessary to republish essentially the same findings?

6\) In [Figure 1F](#fig1){ref-type="fig"}, are the mdx fibers centrally nucleated or not? Is there a quantitative difference in MT organization in Nox2 null mdx mice relative to mdx controls?

7\) It is worth clarifying that the authors are mainly studying the subsarcolemmal MT cytoskeleton just under the, and not that found around the contractile machinery, which has a very different organization. This is important when interpreting the impact of taxol treatment, which will affect both MT pools.

8\) Because of species-specific differences, and to the best of my knowledge, an absence of studies of MT or Nox2 in DMD patient muscle cells, the authors should be careful (e.g., cite appropriately) or avoid claiming (e.g. the first sentence of the Abstract) that what is phenotypically observed in mdx mouse models is recapitulated in DMD patients.

10.7554/eLife.31732.016

Author response

> Essential revisions
>
> All reviewers agreed that the findings described in this manuscript are important and potentially appropriate for publication. However, all reviewers agreed that a major concern needs to be addressed with additional data.
>
> The concern is the reliance on a single histological method -- trichrome staining -- to determine levels of fibrosis. Because of the firmly established patchy nature of fibrosis in mdx diaphragms, this method is not quantitative due to high susceptibility to sampling bias. Because many statistical analyses, and ultimately major conclusions of this study, depend on the accurate quantification of fibrosis, the use of this qualitative approach substantially undermines the conclusions. At least one other more quantitative method, such as western blotting or hydroxyproline measurements -- preferably both -- is needed to increase the confidence in this result. This shouldn\'t be too onerous to perform and feasible in the time allowed for resubmission.

We agree with the concerns raised regarding trichrome staining. We have now added western blot data for Fibronectin and Collagen I along with measurements of hydroxyproline content to [Figure 2](#fig2){ref-type="fig"}. These new data confirm the trichrome data, showing that the increased fibrosis observed in the diaphragm from mdx mice is reduced upon Nox2 inhibition in the mdx/p47-/- mouse model.

> Citations needed
>
> The authors should cite the following studies.
>
> a\) The work of Whitehead et al. (PNAS 2015) showing that treatment of mdx mice with simvastatin reduces NOX2 levels, improves muscle function and reduces (and even reverses) fibrosis in the diaphragm.

We have referenced and cited this work in the Discussion.

> b\) If the authors used the directionality software provided by Liu and Ralston, they must have received a readme file that asked for an acknowledgement in potential publications. This is not out of pure vanity, but as an indication that their software was used, not a home-made version.

We apologize for not appropriately acknowledging that we received and used the directionality algorithm provided by Dr. Ralston. In addition to the existing citation of that work, we have now added this to the acknowledgment section.

> c\) The first study to show aberrant MT organization in dystrophin null muscle fibers was PMID: 17714427 performed by Dr Froehner\'s lab. This study also showed that microdystrophin injection into 1 month old mdx mice is sufficient to prevent the subsequent disorganization of the MT cytoskeleton. Many groups subsequently confirmed these findings several years later.

We have now added the first report by Dr. Froehner's group to our Discussion and citations.

> 1\) In the paper that introduced the mdx/p47KO mouse (Pal et al., 2014) there were several characterizations. Its ROS production was impressively close to that of a wt animal but other properties were not (Ca influx seemed lower than either wt or mdx). Do the authors have evidence that ROS itself is the cause of microtubule and stiffness changes in mdx?

Previous reports have shown that the antioxidant NAC decreased some aspects of dystrophic pathology (Whitehead et al. J. Physiol. 2008), they did not access microtubule organization or cell/tissue stiffness. Here, we show with our p47-/-/mdx mouse, which lacks Nox2-dependent ROS production while still lacking dystrophin, that microtubule disorganization and tissue stiffness observed in the mdx mouse is likely due to ROS. We are currently testing whether treatment of mdx with antioxidants such as NAC might also provide protection against microtubule and stiffness changes.

> Muscle microtubule organization is fiber type-dependent (Ralston et al. 1999 & 2001) and regeneration-dependent (Percival et al. 2007, Traffic 8, 1424). Since the mdx/p47KO muscles have more type IIx/IIb fibers than mdx muscles and fewer centrally nucleated fibers, these 2 factors may well contribute to the improvement of microtubules.

We agree with the reviewers and find this an interesting concept. Unfortunately we cannot delineate these contributions from the current data sets. We have acknowledged these possibilities/limitations in the Discussion.

> In Pal et al., the data obtained with the mouse were supplemented with data obtained with inhibitors of Src or of p91. Are there microtubule changes with an acute treatment with p91 peptides?

This is very interesting question. Due to concerns on the bioavailability of the peptide throughout the depth of the tissue we decided not to pursue these experiments.

> 2\) Are the hindlimb muscle microtubules improved in the mdx/p47KO? Emphasis on the diaphragm, linked to mortality in DMD, is valuable. However, in Pompe Disease, a lysosomal storage disorder that affects skeletal and cardiac muscles, enzyme replacement therapy has improved cardiac function, preventing the death of children before age 2, but has not worked as well on skeletal muscles, leaving children and young adults with a longer but often miserable life.

We agree with the reviewers that this is an important idea. This is an ongoing project by another student in the lab in which we are comparing multiple fiber types from limb muscles.

> 3\) The results showing that fibrosis rather than microtubules causes increased stiffness of the mdx diaphragm are compelling, and a warning that the whole muscle needs to be considered when modeling DMD. However the data also show that microtubules would contribute in experiments such as those of Khairallah et al. (2012) that use collagenase dissociated FDB fibers which presumably are freed of the fibrotic layer.

We completely agree with the reviewers comments regarding the importance of the microtubules in cell signaling of isolated fibers. This concept was acknowledged in our discussion, which originally only mentioned C2C12 cells. We now include isolated single fibers (as done in the work by Khairallah et al., 2012) to this discussion.

> 4\) Most papers on the muscle microtubule network look at the dense layer of microtubules between the myofibrillar core and the sarcolemma (Percival et al., 2007; Prins et al., 2009; Khairallah et al., 2012 etc). Loehr et al., however, only examine the core microtubules. Given that both dystrophin and Nox2 are concentrated along the sarcolemma, why this choice? Are the results different (grid vs no-grid) if they look at the surface microtubules?

Indeed, due to the idea that dystrophin binds the MT previous work has focused on either the cortical (Percival et al.; Prins et al.) or some undetermined combination of the cortical and intermyofibrillar MT network (Kerr et al.; Khairallah et al.). However, given the intermyofibrillar MT network surrounds the contractile apparatus, any alterations to this network likely affect force production. In addition, Nox2 is located in the plasma membrane and 60-90% of the plasma membrane in skeletal muscle is comprised by the t-tubules. Therefore, the intermyofibrillar MT network likely contributes more to muscle function and the mechanical activation of Nox2 ROS compared with the cortical MT network and therefore we focused on the intemyofibrillar MT network. We have added a discussion of this.

> 5\) Clarification of overlap between the current study and what the authors have published previously. Using this model the authors previously reported (Pal et al., 2014, Loehr et al., 2016) that loss of Nox2 improved dystrophic muscle pathology (reduced central nucleation, macrophage infiltration, diaphragm weakness across a range of stimulation frequencies and normalized fiber type composition). Very similar data found in Pal et al., 2014 appears again in this study in [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}. The authors do state that\"... eliminating Nox2 ROS production in young mdx mice can protect against diaphragm alterations (Pal et al., 2014).\" But is it necessary to republish essentially the same findings?

Given muscle dysfunction in dystrophy is progressive, we wanted to determine whether eliminating Nox2 ROS provided protection against muscle/diaphragm

dysfunction in older dystrophic mice. This information is critical. If we found that eliminating Nox2 ROS was only protective in young and not adult we would have drawn a different conclusion regarding the therapeutic potential of targeting Nox2. Therefore, we do not feel this is "republishing essentially the same findings". We have elaborated on this and hopefully the rationale is now clearer.

> 6\) In [Figure 1F](#fig1){ref-type="fig"}, are the mdx fibers centrally nucleated or not? Is there a quantitative difference in MT organization in Nox2 null mdx mice relative to mdx controls?

While the mdx fibers have central nuclei, we decided to analyze density and organization in areas away from the nuclei to avoid confounding issues with the MT network around nuclei, which is also different around peripheral nuclei compared to the cortical MT network away from nuclei. Due to the complexities of generating Nox2 null mdx mice (both genes are X-linked) we elected to take the simpler approach of generating the p47-/-/mdx mouse line reported here.

> 7\) It is worth clarifying that the authors are mainly studying the subsarcolemmal MT cytoskeleton just under the, and not that found around the contractile machinery, which has a very different organization. This is important when interpreting the impact of taxol treatment, which will affect both MT pools.

We are actually studying the MT network around the contractile machinery and not the cortical/subsarcolemmal MT network. We have clarified this and provided the rationale for this in response to point 4 above.

8\) Because of species-specific differences, and to the best of my knowledge, an absence of studies of MT or Nox2 in DMD patient muscle cells, the authors should be careful (e.g., cite appropriately) or avoid claiming (e.g. the first sentence of the Abstract) that what is phenotypically observed in mdx mouse models is recapitulated in DMD patients.

We thank the reviewers for pointing out our overstatements. We have corrected this in the manuscript.
